vs
Side-by-side financial comparison of Hyatt Hotels Corp (H) and Hologic (HOLX). Click either name above to swap in a different company.
Hyatt Hotels Corp is the larger business by last-quarter revenue ($1.8B vs $1.0B, roughly 1.7× Hologic). Hologic runs the higher net margin — 17.1% vs -1.1%, a 18.2% gap on every dollar of revenue. On growth, Hyatt Hotels Corp posted the faster year-over-year revenue change (11.7% vs 2.5%). Hyatt Hotels Corp produced more free cash flow last quarter ($236.0M vs $215.2M). Over the past eight quarters, Hyatt Hotels Corp's revenue compounded faster (2.2% CAGR vs 1.5%).
Hyatt Hotels Corporation, commonly known as Hyatt Hotels & Resorts, is an American multinational hospitality company headquartered in the Riverside Plaza area of Chicago that manages and franchises luxury and business hotels, resorts, and vacation properties. Hyatt Hotels & Resorts is one of the businesses managed by the Pritzker family. Hyatt has more than 1350 hotels and all-inclusive properties in 69 countries, across North America, South America, Europe, Asia, Africa and Australia.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
H vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $1.0B |
| Net Profit | $-20.0M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 0.4% | 22.6% |
| Net Margin | -1.1% | 17.1% |
| Revenue YoY | 11.7% | 2.5% |
| Net Profit YoY | 64.3% | -10.9% |
| EPS (diluted) | $-0.20 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.8B | $1.0B | ||
| Q3 25 | $1.8B | $1.0B | ||
| Q2 25 | $1.8B | $1.0B | ||
| Q1 25 | $1.7B | $1.0B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.6B | $988.0M | ||
| Q2 24 | $1.7B | $1.0B | ||
| Q1 24 | $1.7B | $1.0B |
| Q4 25 | $-20.0M | $179.1M | ||
| Q3 25 | $-49.0M | $187.2M | ||
| Q2 25 | $-3.0M | $194.9M | ||
| Q1 25 | $20.0M | $-17.4M | ||
| Q4 24 | $-56.0M | $201.0M | ||
| Q3 24 | $471.0M | $178.6M | ||
| Q2 24 | $359.0M | $194.5M | ||
| Q1 24 | $522.0M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | 0.4% | 22.6% | ||
| Q3 25 | -1.0% | 22.6% | ||
| Q2 25 | 2.1% | 24.9% | ||
| Q1 25 | 3.0% | -0.7% | ||
| Q4 24 | -3.0% | 22.5% | ||
| Q3 24 | 37.3% | 23.3% | ||
| Q2 24 | 27.1% | 24.1% | ||
| Q1 24 | 31.6% | 20.7% |
| Q4 25 | -1.1% | 17.1% | ||
| Q3 25 | -2.7% | 17.8% | ||
| Q2 25 | -0.2% | 19.0% | ||
| Q1 25 | 1.2% | -1.7% | ||
| Q4 24 | -3.5% | 19.7% | ||
| Q3 24 | 28.9% | 18.1% | ||
| Q2 24 | 21.1% | 19.2% | ||
| Q1 24 | 30.5% | 16.7% |
| Q4 25 | $-0.20 | $0.79 | ||
| Q3 25 | $-0.51 | $0.84 | ||
| Q2 25 | $-0.03 | $0.86 | ||
| Q1 25 | $0.19 | $-0.08 | ||
| Q4 24 | $-0.37 | $0.87 | ||
| Q3 24 | $4.63 | $0.75 | ||
| Q2 24 | $3.46 | $0.82 | ||
| Q1 24 | $4.93 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $813.0M | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $3.3B | $5.2B |
| Total Assets | $14.0B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $813.0M | $2.4B | ||
| Q3 25 | $749.0M | $2.2B | ||
| Q2 25 | $912.0M | $1.9B | ||
| Q1 25 | $1.8B | $1.6B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.1B | $2.3B | ||
| Q2 24 | $2.0B | $2.4B | ||
| Q1 24 | $794.0M | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $6.0B | $2.5B | ||
| Q2 25 | $6.0B | $2.5B | ||
| Q1 25 | $4.3B | $2.5B | ||
| Q4 24 | $3.8B | $2.5B | ||
| Q3 24 | $3.1B | $2.5B | ||
| Q2 24 | $3.9B | $2.5B | ||
| Q1 24 | $3.1B | $2.6B |
| Q4 25 | $3.3B | $5.2B | ||
| Q3 25 | $3.5B | $5.0B | ||
| Q2 25 | $3.6B | $4.8B | ||
| Q1 25 | $3.5B | $4.6B | ||
| Q4 24 | $3.5B | $4.8B | ||
| Q3 24 | $3.7B | $5.1B | ||
| Q2 24 | $3.9B | $5.0B | ||
| Q1 24 | $3.7B | $4.8B |
| Q4 25 | $14.0B | $9.2B | ||
| Q3 25 | $15.7B | $9.0B | ||
| Q2 25 | $15.9B | $8.8B | ||
| Q1 25 | $14.0B | $8.5B | ||
| Q4 24 | $13.3B | $8.7B | ||
| Q3 24 | $11.9B | $9.2B | ||
| Q2 24 | $12.8B | $8.9B | ||
| Q1 24 | $11.7B | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | 1.73× | 0.50× | ||
| Q2 25 | 1.69× | 0.52× | ||
| Q1 25 | 1.25× | 0.55× | ||
| Q4 24 | 1.07× | 0.53× | ||
| Q3 24 | 0.85× | 0.49× | ||
| Q2 24 | 1.01× | 0.51× | ||
| Q1 24 | 0.84× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $313.0M | $229.9M |
| Free Cash FlowOCF − Capex | $236.0M | $215.2M |
| FCF MarginFCF / Revenue | 13.2% | 20.5% |
| Capex IntensityCapex / Revenue | 4.3% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $159.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $313.0M | $229.9M | ||
| Q3 25 | $-20.0M | $355.1M | ||
| Q2 25 | $-67.0M | $343.3M | ||
| Q1 25 | $153.0M | $169.4M | ||
| Q4 24 | $235.0M | $189.3M | ||
| Q3 24 | $-21.0M | $367.0M | ||
| Q2 24 | $177.0M | $405.8M | ||
| Q1 24 | $242.0M | $292.4M |
| Q4 25 | $236.0M | $215.2M | ||
| Q3 25 | $-89.0M | $341.4M | ||
| Q2 25 | $-111.0M | $330.5M | ||
| Q1 25 | $123.0M | $153.9M | ||
| Q4 24 | $184.0M | $172.5M | ||
| Q3 24 | $-64.0M | $350.6M | ||
| Q2 24 | $135.0M | $385.3M | ||
| Q1 24 | $208.0M | $279.6M |
| Q4 25 | 13.2% | 20.5% | ||
| Q3 25 | -5.0% | 32.5% | ||
| Q2 25 | -6.1% | 32.3% | ||
| Q1 25 | 7.2% | 15.3% | ||
| Q4 24 | 11.5% | 16.9% | ||
| Q3 24 | -3.9% | 35.5% | ||
| Q2 24 | 7.9% | 38.1% | ||
| Q1 24 | 12.1% | 27.5% |
| Q4 25 | 4.3% | 1.4% | ||
| Q3 25 | 3.9% | 1.3% | ||
| Q2 25 | 2.4% | 1.3% | ||
| Q1 25 | 1.7% | 1.5% | ||
| Q4 24 | 3.2% | 1.6% | ||
| Q3 24 | 2.6% | 1.7% | ||
| Q2 24 | 2.5% | 2.0% | ||
| Q1 24 | 2.0% | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 1.90× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | 7.65× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | -0.04× | 2.05× | ||
| Q2 24 | 0.49× | 2.09× | ||
| Q1 24 | 0.46× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
H
| Other | $627.0M | 35% |
| Rooms Revenue | $326.0M | 18% |
| Net Fees | $290.0M | 16% |
| Distribution Segment | $177.0M | 10% |
| Franchise And Other Fees | $114.0M | 6% |
| Base Management Fees | $112.0M | 6% |
| Incentive Management Fees | $81.0M | 5% |
| Other Owned And Leased Hotel Revenue | $41.0M | 2% |
| Contra Revenue | $17.0M | 1% |
| Other Revenues | $4.0M | 0% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
